Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2015

View Archived Issues

Transformed porcine mammary epithelial cells form xenograft tumors in mice

MAF is a biomarker of breast cancer bone metastasis

MedImmune initiates phase I study of MEDI-9197 for solid tumor cancers

PTP1B shows promise for the improvement of islet graft revascularization

Daiichi Sankyo divulges EZH1/EZH2 inhibitors

MyoKardia provides update on two phase I trials of MYK-461

Osiris begins phase III trial of OTI-15-01 in chronic diabetic foot wounds

Abeona Therapeutics forms license agreement for next-generation AAV delivery vector

Serendex reports results from phase I trial of inhaled GM-CSF

GreenPeptide files IND for cancer peptide vaccine GRN-1201

FDA grants priority review to Daklinza supplemental NDAs

Avelumab receives FDA fast track designation for metastatic Merkel cell carcinoma

Novel insulin mutation linked to autosomal dominant diabetes

Nektar submits IND for NKTR-214 to treat solid tumor malignancies

Paranta Biosciences starts phase I trial of inhaled follistatin

Bristol-Myers Squibb introduces NS5B inhibitors

Capella Therapeutics patents EGFR inhibitors

Bayer Schering Pharma divulges Wnt signaling inhibitors

Agios presents glutaminase inhibitors

MD Anderson and Theraclone partner to launch new company OncoResponse

DeNovo Sciences and bioTheranostics to collaborate on detection of cancer biomarkers in blood

Octapharma acquires license to Glycotope's recombinant technology, takes shareholding

FDA grants rare pediatric disease designation to deflazacort for DMD

Nivalis announces topline results from phase Ib study of N-91115 in cystic fibrosis

RATHER collaboration reports on phase II trial of taselisib in hard-to-treat breast cancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...